Compugen (CGEN)

Compugen’s pipeline includes several clinical-stage programs directed at targets the company discovered through its computational approach. COM701 targets PVRIG, while COM902 targets TIGIT, both of which are part of the broader DNAM axis of immune regulation. The company is also associated with rilvegostomig and GS-0321, previously known as COM503, as part of its immuno-oncology development and collaboration activities.

The company’s business model combines internal drug development with partnerships and licensing agreements. Revenue is generated primarily from collaboration and licence arrangements rather than commercial product sales, reflecting its stage of development. Its reported revenue is geographically concentrated in the United Kingdom, with additional contribution from the United States.

For investors, Compugen is distinguished by the link between its computational target-discovery capabilities and a clinical pipeline aimed at next-generation immuno-oncology. The company’s prospects depend on the quality of clinical data, the validation of its targets, the durability of partner relationships, and its ability to advance therapies through regulatory development. As with many clinical-stage biotechnology companies, its valuation can be highly sensitive to trial results, milestone payments, financing needs, and broader sentiment toward cancer immunotherapy.